Clinical Trials Logo

Carcinoma, Renal Cell clinical trials

View clinical trials related to Carcinoma, Renal Cell.

Filter by:

NCT ID: NCT01038778 Active, not recruiting - Clinical trials for Clear Cell Renal Cell Carcinoma

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Start date: October 29, 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of entinostat when given together with aldesleukin and to see how well this works in treating patients with kidney cancer that has spread to other places in the body. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Aldesleukin may stimulate the white blood cells to kill kidney cancer cells. Giving entinostat together with aldesleukin may be a better treatment for metastatic kidney cancer.

NCT ID: NCT00945984 Active, not recruiting - Clinical trials for Localized Renal Cell Carcinoma

Laparoendoscopic Single-site Radical Nephrectomy for Localized Renal Cell Carcinoma

LESS
Start date: March 2009
Phase: N/A
Study type: Observational

Surgical resection is the only potential curative treatment available for renal cell carcinoma. The purpose of this study is to clarify the surgical and oncologic outcomes of laparoendoscopic single-site radical nephrectomy for localized Renal Cell Carcinoma.

NCT ID: NCT00934440 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma

5-AZ
Start date: June 2009
Phase: Phase 1/Phase 2
Study type: Interventional

To identify the maximum tolerable dose and assess qualitative/quantitative toxicities in patients with advanced renal cell cancer treated with combination of 5-azacitidine and bevacizumab.

NCT ID: NCT00918775 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Follow-up After Metastasectomy in Patients With Kidney Cancer

Start date: June 9, 2009
Phase:
Study type: Observational

This phase II trial studies the follow-up after metastasectomy in patients with kidney cancer. Following up patients' health condition after metastasectomy may help doctors to learn if the surgical removal of the primary tumor or the parts of the cancer that has spread to other parts of the body is a good method for treating patients who have kidney cancer.

NCT ID: NCT00835978 Active, not recruiting - Clinical trials for Carcinoma, Renal Cell

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Start date: August 2009
Phase: Phase 2
Study type: Interventional

Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.

NCT ID: NCT00740441 Active, not recruiting - Clinical trials for Metastatic Renal Cell Carcinoma

A Phase II Study of AS1411 in Renal Cell Carcinoma

Start date: August 2008
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal Cell Carcinoma

NCT ID: NCT00715442 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

Start date: June 24, 2008
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if Sutent® (sunitinib malate), given before surgery, can help control renal cell carcinoma. The safety of sunitinib malate will also be studied.

NCT ID: NCT00600496 Active, not recruiting - Breast Cancer Clinical Trials

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Start date: December 14, 2007
Phase: Phase 1
Study type: Interventional

This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. The study will also investigate how AZD6244 in combination with standard chemotherapies are absorbed, distributed and excreted by the body as well as the length of time that the drugs remain in the body. Initial and periodic assessments will establish patient response to the combination therapies

NCT ID: NCT00531284 Active, not recruiting - Multiple Myeloma Clinical Trials

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma

Start date: September 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of this Phase 1b/2 study were as follows: - Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in patients with relapsed solid tumors and in patients with relapsed and/or refractory multiple myeloma and in patients with refractory lymphoma. - Phase 2 (Bolus): To evaluate the overall response rate (ORR) after 4 cycles of carfilzomib in patients with relapsed solid tumors.

NCT ID: NCT00423332 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Start date: January 2007
Phase: Phase 2
Study type: Interventional

Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.